AUPH News and Press, Aurinia Pharmaceuticals Inc From 07/01/22

Shares of the commercial-stage biopharma Aurinia Pharmaceuticals (NASDAQ: AUPH) rose by as much as 13.7% during Friday's trading session. The drugmaker's stock perked up today in response to yet another buyout rumor. This time around, Japanese drug manufacturer Otsuka Hold...

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 8% on speculation the company may be a target for Otsuka ( OTCPK:OTSKF ). Aurinia ( AUPH ) could be a potential takeover target for Otuska, according to a Betaville item earlier. Recall late May, Aurinia Pharmac...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that the Company’s Compensation Committee granted 11 new employees inducement stock ...

At 2022 Russell indexes annual reconstitution, following notable health care stocks will be added to and deleted from the Russell 3000 Index. Notable additions: Clover Health Investments (CLOV), Aurinia Pharmaceuticals (AUPH), Nano-X Imaging (NNOX), ADMA Biologics (ADMA),&...

-The post-hoc analysis based on the updated treatment recommendations was presented at the EULAR 2022 European Congress of Rheumatology Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that ...

Aurinia Pharmaceuticals won approval for Lupkynis - to treat Lupus Nephritis - in January 2021. The therapy was considered to have blockbuster (>$1bn per annum) sales potential, but earned only $21.6m in Q1'22. Aurinia management blamed Omicron but will need to show improvement...

Aurinia and its partner OPEL expect a decision from the EMA in the 2nd half of 2022 on whether or not Lupkynis (voclosporin) will be approved for lupus nephritis in the European territories. About $21.6 million in net revenue was generated for Q1 of 2022, due to sales of Lupkynis; if ...

Aurinia Pharmaceuticals (NASDAQ:AUPH) said that data from a study showed that its lupus nephritis treatment Lupkynis (voclosporin) led to preservation of kidney function over three years of treatment. The AURORA 2 study is a continuation study of patients after one year of treatment for anoth...

Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients A pooled analysis from the ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the ...